Document:

EX-10.52

 Exhibit 10.52 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
 LICENSE AGREEMENT 

This LICENSE AGREEMENT (the “Agreement”) is entered into on May 1st, 2015
(the “Effective Date”) between NIPPON KAYAKU CO., LTD., a Japanese corporation with its principal place of business at 1-1, Marunouchi 2-chome, Chiyoda-ku, Tokyo
100-0005, Japan (“KAYAKU”), and EICCOSE PHARMACEUTICALS, LLC, a Delaware corporation with its principal place of business at 1115 Lafayette St., Santa Clara, CA 95050, USA
(“EICCOSE”). KAYAKU and EICCOSE are sometimes referred to herein individually as the “Party”and collectively as the “Parties.” 

RECITALS 

WHEREAS, KAYAKU developed and is selling pharmaceutical products in Japan containing ubenimex as an
active pharmaceutical ingredient for the treatment of cancer and has scientific and technical information relating to such pharmaceutical products; 

WHEREAS, EICCOSE wishes to develop and commercialize pharmaceutical products containing ubenimex for the
treatment of pulmonary arterial hypertension (“PAH”); and 
 WHEREAS, EICCOSE wishes
to use KAYAKU’s scientific and technical information in the development by EICCOSE of such pharmaceutical products for PAH, and KAYAKU is willing to grant to EICCOSE a right to develop and commercialize such pharmaceutical products for PAH
using such KAYAKU’s scientific and technical information. 
 NOW THEREFORE, in
consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties agree as follows: 
  

	ARTICLE	1  DEFINITIONS 

 As used in this Agreement, the following initially capitalized
terms, whether used in the singular or plural form, shall have the meanings set forth in this Article 1. 
 1.1
“Affiliate” means, with respect to a particular Party, a person, corporation, partnership, or other entity that controls, is controlled by, or is under common control with such Party. For the purposes of this definition, the
word “control” (including, with correlative meaning, the terms “controlled by” or “under the common control with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct or
cause the direction of the management and policies of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, or by contract or otherwise. 

  
 Page 1 of 29 

 1.2 “API” means Ubenimex (INN), an active pharmaceutical ingredient. 

1.3 “Confidential Information” means, with respect to the Party, all reports and other Information (as defined below)
that are disclosed by such Party to the other Party under this Agreement, whether in oral, written, graphic, electronic or other form. In addition, any Information that was disclosed by one Party to the other Party pursuant to the SECRECY AGREEMENT
between the Parties signed on October 29, 2012/October 26, 2012, that was subject to obligations of confidentiality under the terms of that agreement, shall be deemed to be such disclosing Party’s Confidential Information hereunder. 

1.4 “Control” means, with respect to any material, Information, Know-How, Patents, or other intellectual property
rights, that a Party or its sublicensees own or have a license to such material, Information, Know-How, Patents, or other intellectual property rights, and, in each case, the Party has the ability to grant, or such sublicensees have the ability to
grant through such Party, to the other Party access, a license, or a sublicense (as applicable) to the same. 
 1.5 “EICCOSE
Territory” means the whole world excluding KAYAKU Territory. 
 1.6 “Field” means the treatment of any
inflammatory disease involving leukotriene B4, including but not limited to, pulmonary arterial hypertension (PAH), in humans. For the avoidance of doubt, the Field shall not include the treatment of acute non-lymphatic leukemia. 

1.7 “First Commercial Sale” means the first sale by a Party or its sublicensees hereunder to a Third Party of the
Product in the Field in a given regulatory jurisdiction after the Regulatory Approval for the Product has been obtained in such jurisdiction. 

1.8 “Governmental Authority” means any multi-national, federal, state, local, municipal, provincial or other government
authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court, or other tribunal). 

1.9 “Information” means any information of any type whatsoever, in any tangible or intangible form, including, without
limitation, data, results, technology, Regulatory Filings, trade secrets, practices, techniques, methods, processes, inventions, developments, specifications, formulations, formulae, materials or compositions of matter of any type or kind
(patentable or otherwise), software, algorithms, marketing and sales reports, expertise, technology, test data (including pharmacological, biological, chemical, biochemical, toxicological, preclinical and clinical test data), analytical and quality
control data, stability data, other study data, and procedures. 
 1.10 “KAYAKU Territory” means the countries
of Japan, China, Taiwan, Hong Kong, India, Indonesia, Malaysia, Korea, Philippines, Singapore, Thailand, Macao, Mongolia, Cambodia, Laos, Brunei, Myanmar, Bangladesh, Nepal, Bhutan, Maldives, Sri Lanka, Pakistan, Afghanistan, Tajikistan, Uzbekistan,
Kazakhstan, Kyrgyz, Turkmenistan, Azerbaijan, Armenia, and Vietnam. 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 2 of 29 

 1.11 “Know-How” means all Information owned or Controlled by a Party or
its sublicensees as of the Effective Date or during the Term which is necessary or reasonably useful for the development, obtaining Regulatory Approval and/or commercialization of the Product in the Field in accordance with the terms of this
Agreement. For clarity, (i) Know-How includes all data, results and other Information generated from or obtained by the development conducted by or for either Party or its sublicensees under this Agreement, and (ii) KAYAKU’s Know-How
includes any Information described in the Regulatory Filings filed by KAYAKU with any Regulatory Authority prior to and after the Effective Date with respect to any pharmaceutical product containing API. Information relating to the manufacture of
API (“Manufacturing Know-How”) shall be included in the Know-How and transferred only as provided in Section 5.3 of this Agreement. 

1.12 “Laws” means all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law
of any federal, national, multinational, state, provincial, county, city, or other political subdivision, domestic or foreign. 

1.13 “Net Sales” means, with respect to a particular time period, the total amounts invoiced by KAYAKU or its
sublicensees for sales of the Product in the Field made during such time period to any Third Party, less the following deductions to the extent actually allowed or incurred with respect to such sales of Product: 

(a) reasonable and customary discounts, including cash and quantity discounts, charge-back payments, administrative fees incurred
directly in such discounting, and rebates actually granted to trade customers and distributors (including wholesalers); 
 (b)
reasonable and customary credits or allowances actually granted for damaged, outdated, spoiled, returned, or rejected Product, including, without limitation, in connection with recalls; and 

(c) taxes (including consumption taxes), tariffs, duties, or other governmental charges (other than income taxes) levied on, absorbed,
or otherwise imposed on sales or transfers of the Product in the KAYAKU Territory, as adjusted by any refunds, provided that such taxes, tariffs, duties, or other government charges are included in the applicable invoiced amount and identified in
the applicable invoice. 
 Notwithstanding the foregoing, amounts billed by KAYAKU for the sale of the Product between KAYAKU and its sublicensees for
resale shall not be included in the computation of Net Sales hereunder so long as the running royalty is paid on such sublicensees’ sale of such Product. A sale of the Product by KAYAKU or its sublicensees to a wholesaler shall be regarded as
the sale of the Product to a Third Party for the purpose of calculating the Net Sales. For purposes of determining the Net Sales, the Product shall be deemed to be sold when shipped and a “sale” shall not include reasonable transfers or
dispositions as samples or for charitable purposes, or transfers or dispositions for preclinical, clinical or regulatory purposes, provided no compensation is paid to KAYAKU or its sublicensee therefor.

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 3 of 29 

 
Each of the deductions set forth above shall be reasonable and customary, and in accordance with accounting principles generally accepted in Japan or otherwise in the country of sale in the
KAYAKU Territory. 
 1.14 “Patents” means (a) pending patent applications, issued patents, utility models, and
designs; (b) reissues, substitutions, confirmations, registrations, validations, re-examinations, additions, continuations, continued prosecution applications, continuations-in-part, or divisions of or to any patents, patent applications,
utility models, or designs; and (c) the equivalent or counterpart of the foregoing, that (i) are owned or Controlled by a Party or its sublicensees as of the Effective Date or during the Term, and (ii) but for the licenses granted
herein, would be infringed by the developing, making, using, and/or selling of the Product by the other Party or its sublicensees in the Field. As of the Effective Date, KAYAKU represents that it has no valid Patents covering the Product for use in
the Field. 
 1.15 “Product” means any pharmaceutical product containing API. 

1.16 “Regulatory Approval” means, with respect to the Product in any country or jurisdiction, all approvals (including,
where required, pricing and reimbursement approvals), registrations, licenses, or authorizations from the relevant Regulatory Authority in a country or jurisdiction that is specific to the Product and necessary to market and sell such Product in
such country or jurisdiction. 
 1.17 “Regulatory Authority” means, in a particular country or regulatory
jurisdiction, any applicable Governmental Authority involved in granting Regulatory Approval and/or, to the extent required in such country or regulatory jurisdiction, pricing or reimbursement approval of the Product in such country or regulatory
jurisdiction. 
 1.18 “Regulatory Filings” means, with respect to the Product, any submission to a Regulatory
Authority of any appropriate regulatory application specific to the Product, and shall include, without limitation, any submission to a regulatory advisory board and any supplement or amendment thereto.  

1.19 “Royalty Term” has the meaning set forth in Section 6.1(a). 

1.20 “Study Product” means a pharmaceutical product containing API for use in the development of the Product by or on
behalf of EICCOSE or its sublicensees under this Agreement that is (i) Bestatin (ubenimex) 30 mg Immediate Release Capsules (the currently marketed formulation in Japan) in commercial capsule form or unmarked capsule form, or (ii) any
other pharmaceutical product containing API that is agreed by the Parties and supplied by KAYAKU to EICCOSE or its sublicensees. 
 1.21
“Term” means the term of this Agreement, as determined in accordance with Section 11.1. 
 1.22
“Territory” means the EICCOSE Territory or the KAYAKU Territory. 
 1.23 “Third Party” means any
person or entity other than KAYAKU or EICCOSE. 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 4 of 29 

 1.24 “Valid Claim” means, with respect to any country: (a) a claim
of an issued and unexpired patent (as may be extended through supplementary protection certificate or patent term extension or the like) included within the Patents to the extent such claim has not been revoked, held invalid or unenforceable by a
patent office, court or other governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time period) and which claim has not been disclaimed, denied or
admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise; and (b) a claim of a pending patent application included within the Patents. 

ARTICLE 2  LICENSES AND EXCLUSIVITY 

2.1 License to EICCOSE by KAYAKU.  

(a) License. Subject to the terms of this Agreement, (i) KAYAKU hereby grants EICCOSE an exclusive license with the right to grant
sublicenses, under the Know-How owned or Controlled by KAYAKU as of the Effective Date, to develop, manufacture, use, market, sell and otherwise commercialize the Product in the Field in the EICCOSE Territory, and (ii) KAYAKU hereby grants
EICCOSE an exclusive license with the right to grant sublicenses, under the Know-How and the Patents owned or Controlled by KAYAKU or its sublicensees after the Effective Date as a result of the development under the license granted to KAYAKU
pursuant to Section 2.2(a), to develop, manufacture, use, market, sell and otherwise commercialize the Product in the Field in the EICCOSE Territory. 

(b) License fees. Subject to the terms of this Agreement and except as otherwise provided for herein, EICCOSE shall not be obligated to
pay KAYAKU any initial, upfront, or milestone payments or any other royalties or license fees for the grant of such license to EICCOSE pursuant to Section 2.1(a). 

(c) Sublicensees’ rights and obligations. Each sublicense agreement between EICCOSE and any sublicensee of EICCOSE under this
Agreement shall not conflict with the terms and conditions of this Agreement. EICCOSE shall, in each sublicense agreement under which it grants a sublicense under the license set forth in Section 2.1(a), include among others the following terms
and conditions: (i) EICCOSE’s sublicensees shall grant EICCOSE the rights to grant KAYAKU an exclusive license with the right to grant sublicenses pursuant to Section 2.2(a) under the Know-How and the Patents owned or Controlled by
EICCOSE’s sublicensees; (ii) EICCOSE’s sublicensees shall have the right to purchase from KAYAKU those quantities of the Study Product (or bulk material of API for use therein) needed for such sublicensees to conduct the development,
so long as KAYAKU is able to supply such Study Product (or bulk material of API for use therein) in the amounts and at the price set forth in Section 3.1(e), (f) and, at their option, (g); (iii) EICCOSE’s sublicensees shall have
the right to purchase from KAYAKU those quantities of the Study Product and Product (or bulk material of API for use therein) needed for such sublicensees to conduct Phase 3 clinical testing and sell the Product commercially, so long as KAYAKU is
able to supply such Product (or bulk material of API for use therein) in the amounts and at the commercially reasonable prices set forth in Section 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 5 of 29 

 
3.1(f) and (g) and Section 5.3 or at its option to manufacture such Study Product and Product and pay the royalty due on Net Sales of Product as provided in Section 5.3; and
(iv) EICCOSE’s sublicensees shall bear the same secrecy and non-use obligations as EICCOSE bears under Article 10. EICCOSE shall remain primarily responsible for the performance of such obligations of EICCOSE’ sublicensees by each of
such sublicensees. 
 (d) Sublicenses. EICCOSE shall, within thirty (30) days after granting any sublicense under
Section 2.1(a) above, notify KAYAKU of the grant of such sublicense and provide KAYAKU with a true and complete copy of such sublicense agreement. 

(e) Disclosure of Know-How by KAYAKU; Filing and Maintenance of and access to Drug Master File. KAYAKU shall, as soon as practicable
after the Effective Date but in no event later than [ * ] after the Effective Date, and from time to time thereafter during the Term, promptly disclose to EICCOSE all of the Know-How owned or Controlled by KAYAKU or its sublicensees use of which is
granted hereunder and which is material or necessary or helpful for the development, Regulatory Approval and commercialization of the Product by EICCOSE or its sublicensees. EICCOSE shall be responsible for translating, at its own costs, any reports
or other documents written in Japanese from Japanese language into English language as needed for review or for purposes of submission to the Regulatory Authority or for any other purposes. Further, KAYAKU shall file or cause to be filed a complete
Drug Master File (“DMF”) for the API with the United States Food and Drug Administration (“FDA”) within [ * ] of the Effective Date and shall maintain such file as the FDA requires throughout the Term. In addition, KAYAKU shall
file or cause to be filed a DMF or equivalent in any other country in the EICCOSE Territory within [ * ] of EICCOSE’s reasonable written request. For clarity, the obligations pursuant to this Section 2.1(e) include disclosure of any
Information included in such DMF or equivalent reasonably necessary to obtain Regulatory Approval in the EICCOSE Territory. Should KAYAKU fail to perform its obligations relating to such DMF or equivalent under this Section 2.1(e) in time, then
KAYAKU shall provide all Information relating to the manufacture of API to EICCOSE, which Information shall then become Know-How under Section 1.11. 

(f) License by KAYAKU outside the Field. During the first [ * ] following the Effective Date, KAYAKU shall not grant any Third Party a
license under Information set forth in (ii) of Section 1.11 to develop, manufacture, use, market, sell and otherwise commercialize the Product outside the Field in the EICCOSE Territory without prior written consent of EICCOSE, and
thereafter, such a license may be granted to a Third Party only if the following process has been followed. Following the [ * ] of the Effective Date and at least [ * ] prior to offering such license to a third party, KAYAKU shall first notify
EICCOSE of its intent to license together with the material terms of such license, including the purpose of such license, the disease(s) to be treated with the API, and the financial terms; provided, however, that EICCOSE shall bear and perform the
confidentiality, limited-use and other obligations as required in the non-disclosure agreement between KAYAKU and such third party or otherwise required by KAYAKU. EICCOSE shall have the opportunity to take the license on such terms. EICCOSE must
provide its decision whether to take the license within [ * ] after EICCOSE is so informed by KAYAKU. If EICCOSE does not take the license, KAYAKU may then offer a license to a third party on such terms but may not materially change those terms
without first 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 6 of 29 

 
offering the materially changed terms to EICCOSE as provided in this Section 2.1(f). Notwithstanding the foregoing, KAYAKU may grant a Third Party such license under Information set forth in
(ii) of Section 1.11 outside the Field in the EICCOSE Territory without prior written consent of EICCOSE if (i) EICCOSE or its sublicensee has not [ * ] under this Agreement within [ * ] of the Effective Date, (ii) after making [
* ] under this Agreement, EICCOSE or its sublicensee does not [ * ], (iii) EICCOSE or its sublicensee [ * ] after the Effective Date, (iv) EICCOSE or its sublicensee [ * ] under this Agreement within [ * ] after the Effective Date,
(v) EICCOSE or its sublicensee [ * ] under this Agreement, or (vi) EICCOSE or its sublicensee [ * ] under this Agreement. 
 (g)
License by KAYAKU in the KAYAKU Territory. Subject to EICCOSE meeting the requirements of Section 2.1(f), and subject to KAYAKU’s rights of selling bulk material of research grade, non-clinical API to Peptides International (which
relationship will not be expanded beyond the relationship as of the Effective Date; see http://pepnet.com/ShoppingUsers/ProductDetails/IBSPI-1228.aspx), KAYAKU shall not supply Product or license Patents or Know-How with respect to the
Product in the KAYAKU Territory to any Third Party that it reasonably knows or becomes aware of importing or selling such Product into the EICCOSE Territory. 

2.2 License to KAYAKU by EICCOSE. 

(a) License. In consideration of the rights and the licenses granted by KAYAKU to EICCOSE under Section 2.1(a)(i), subject to the
terms of this Agreement, and subject to Section 3.3(a), EICCOSE hereby grants KAYAKU an exclusive license with the right to grant sublicenses, under the Know-How and the Patents owned or Controlled by EICCOSE or its sublicensees, to develop,
manufacture, use, market, sell, and otherwise commercialize the Product in the Field in the KAYAKU Territory. 
 (b) License fees.
Except the payment of the running royalty set forth in Section 2.2(a) during the Royalty Term, KAYAKU shall not be obligated to pay EICCOSE (or Stanford) any initial, upfront or milestone payments or any other royalties or license fees for the
grant of such license to KAYAKU pursuant to Section 2.2(a). For the avoidance of doubt, KAYAKU shall not be obligated to pay EICCOSE any such running royalty after the expiration of the Royalty Term. 

(c) Sublicensees’ obligations. Each sublicense agreement between KAYAKU and any sublicensee of KAYAKU under this Agreement shall
not conflict with the terms and conditions of this Agreement. KAYAKU shall, in each sublicense agreement under which it grants a sublicense under the license set forth in Section 2.2(a), include among others the following terms and conditions:
(i) KAYAKU’s sublicensees shall grant KAYAKU the rights to grant EICCOSE an exclusive license with the right to grant sublicenses pursuant to Section 2.1(a) under the Know-How and the Patents owned or Controlled by KAYAKU’s
sublicensees; and (ii) KAYAKU’s sublicensees shall bear the same secrecy and non-use obligations as KAYAKU bears under Article 10. KAYAKU shall remain primarily responsible for the performance of such obligations of KAYAKU’
sublicensees by each of such sublicensees. 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 7 of 29 

 (d) Sublicenses. KAYAKU shall, within thirty (30) days after granting any sublicense
under Section 2.2(a) above, notify EICCOSE of the grant of such sublicense and provide EICCOSE with a true and complete copy of such sublicense agreement. 

(e) EICCOSE’s First Opportunity. Notwithstanding the above provisions in this Section 2.2, in the event KAYAKU decides to
initiate discussions with a Third Party regarding a sublicense under this Agreement, then KAYAKU shall first so inform EICCOSE of the terms it is seeking, and EICCOSE shall have the opportunity to take the sublicense on such terms. EICCOSE must
provide its decision whether to take the sublicense within [ * ] after EICCOSE is so informed by KAYAKU. If EICCOSE does not take the sublicense within such [ * ], KAYAKU may then offer a sublicense to a third party on such terms but may not
materially change those terms without first offering the materially changed terms to EICCOSE as provided in this section. 
 (f)
Disclosure of Know-How by EICCOSE. EICCOSE shall, as soon as practicable after the Effective Date, and from time to time thereafter during the Term, promptly disclose to KAYAKU all of the Know-How owned or Controlled by EICCOSE or its
sublicensees that is material or necessary or helpful for the development, Regulatory Approval and commercialization of the Product in the KAYAKU Territory by KAYAKU or its sublicensees. 

(g) Stanford Sublicense Requirements. The Parties acknowledge that [ * ] a sublicense under the Stanford License [ * ]. Neither KAYAKU
nor EICCOSE [ * ] would be [ * ]; both acknowledge that [ * ] to their knowledge at present. KAYAKU acknowledges that, [ * ], it must comply with all requirements under the Stanford License specified in Appendix 2.2(g) attached hereto. EICCOSE shall
comply with its obligations specified in Appendix 2.2(g) attached hereto. 
 2.3 Negative Covenant; No Implied License. EICCOSE
covenants that it will not, and it will not permit any of its sublicensees to, use or practice any Know-How and Patents owned or Controlled by KAYAKU or its sublicensees outside the scope of the license granted to it under Section 2.1 above.
KAYAKU covenants that it will not, and it will not permit any of its sublicensees to, use or practice any Know-How and Patents owned or Controlled by EICCOSE or its sublicensees outside the scope of the license granted to it under Section 2.2
above. Except as set forth herein, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, under any trademarks, patents or patent applications owned or Controlled by the other Party or its
sublicensees. 
 ARTICLE 3  PRODUCT DEVELOPMENT 

3.1 Development by EICCOSE.  

(a) EICCOSE shall conduct development of the Product in the EICCOSE Territory in accordance with the development plan attached hereto as
Exhibit A and shall comply 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 8 of 29 

 
with all applicable Laws. From time to time during the Term, EICCOSE may update and amend the then-current development plan and, in such event, shall provide KAYAKU with a copy of such updated or
amended development plan. EICCOSE shall provide KAYAKU with a written report on the status and progress of development activities on a [ * ]. 

(b) Promptly after the Effective Date, EICCOSE shall seek US and EU regulatory guidance on the utility of KAYAKU preclinical and
clinical data on file for purposes of development in the EICCOSE Territory. 
 (c) Promptly but in any event within [ * ] after the
Effective Date, KAYAKU shall assign to EICCOSE its US IND for the Product and EICCOSE shall undertake and be responsible for all development, including without limitation clinical development, of the Product in the EICCOSE Territory. EICCOSE
acknowledges that the KAYAKU IND in the US is inactive or has been withdrawn for purposes of Regulatory Approval. 
 (d) All
Information generated in the development activities hereunder by or for EICCOSE or its sublicensees shall be the property of EICCOSE, its sublicensees, and/or its or their collaborators. In the event such Information is made by such sublicensees,
EICCOSE shall ensure that such Information and Patents for inventions in such Information are included in the Know-How and the Patents owned or Controlled by its sublicensees and can be used by KAYAKU or its sublicensees under the license granted
pursuant to Section 2.2(a). In the event such Information is made by such collaborators, EICCOSE shall, and shall cause its sublicensees to, make reasonable best efforts to own or Control such Information and Patents for inventions in such
Information so that such Information and Patents are included in the Know-How and the Patents owned or Controlled by EICCOSE or its sublicensees as the case may be and can be used by KAYAKU or its sublicensees under the license granted pursuant to
Section 2.2(a). 
 (e) Provided KAYAKU is in and maintains compliance with all laws and regulatory requirements for clinical
development and sale of Products in the EICCOSE Territory, EICCOSE shall purchase from KAYAKU and KAYAKU shall provide to EICCOSE the quantities of the Study Product (or bulk material of API for use therein) needed for EICCOSE to develop the Product
for the Regulatory Approval as provided herein. EICCOSE shall purchase from KAYAKU sufficient Study Product (or bulk material of API for use therein) for use in its Phase 2 studies conducted by or for EICCOSE at either the Japanese Health Authority
approved price or at a price set forth below in case of bulk material of API. The first purchase, of Phase 2 supplies, will be due after the Regulatory Authority approval of a new US IND filed by EICCOSE to permit study of the Study Product in the
US. 
 (f) Within [ * ] of the Effective Date, EICCOSE shall place a binding order for Study Product for Phase 2 studies from KAYAKU,
and KAYAKU shall sell to EICCOSE the Study Product meeting the specifications required by EICCOSE to be used as clinical trial material for Phase 2 studies. The price per 30 mg of API contained in the Study Product will be [ * ]. However, in the
event the bulk material of API is supplied in lieu of the Study Product, the price per 30 mg shall be [ * ] Promptly after the initiation of Phase 2 studies, EICCOSE shall notify KAYAKU whether it wishes to transfer manufacturing to a Third Party as
per Section 5.3 below (the “Manufacturing Option”), or to enter into a supply agreement (the “Supply Agreement”). If 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 9 of 29 

 
EICCOSE wishes to enter into a Supply Agreement, then the Parties shall diligently negotiate and enter into the same, which will describe how Product for Phase 3 studies and commercial sale (or
bulk material of API for use therein) will be supplied by KAYAKU to EICCOSE or its sublicensees. The Supply Agreement shall include the following: provisions regarding the frequency with which EICCOSE or its sublicensees may order Product (or bulk
material of API for use therein), any limitations on how much Product (or bulk material of API for use therein) may be ordered at any time, requirements that KAYAKU delivers Product (or bulk material of API for use therein) to EICCOSE or its
sublicensees on time with a cure period [ * ], and the right of EICCOSE to establish a second source of Product such that supply of Product for clinical use or commercial sale will not be interrupted in the event KAYAKU is unable or unwilling to
provide Product for clinical use or commercial sale (or bulk material of API for use therein) as necessary to meet the requirements of EICCOSE and its sublicensees. In any event, the Supply Agreement shall provide for the identification by EICCOSE
of an alternate Third Party manufacturing source acceptable to KAYAKU after the initiation of Phase 3 studies and related disclosure to such Third Party manufacturing source by KAYAKU of Information sufficient to manufacture Product for the EICCOSE
Territory under a secrecy agreement reasonably acceptable to KAYAKU; provided that the second source shall not supply more than [ * ] of EICCOSE’s and its sublicensees’ needs for so long as KAYAKU can provide the remaining [ * ], and is
providing on-time delivery of the total amount of Product (or bulk material of API for use therein) meeting required specifications as ordered by EICCOSE or its sublicensees. Subject to the provision of preceding sentence, EICCOSE may elect to have
such Third Party manufacturing source supply Product for commercial sale for the EICCOSE Territory at any time provided that EICCOSE shall pay to KAYAKU [ * ] of the applicable price per 30 mg of API contained in the Product (or bulk material of
API) set forth in Section 5.3 for Product to be sold that would otherwise apply if KAYAKU supplied such material for such capsule that is supplied by the Third Party manufacturing source unless such supply results from a KAYAKU breach of the
Supply Agreement by KAYAKU or other failure by KAYAKU to timely perform as provided in the Supply Agreement. EICCOSE and KAYAKU shall negotiate the other terms and conditions of the Supply Agreement in good faith and conclude the Supply Agreement
prior to the initiation of the Phase 3 studies, unless EICCOSE exercises its Manufacturing Option, as provide in under Section 5.3 below. 

(g) Provided KAYAKU is in compliance with all laws and regulatory requirements and the Supply Agreement, EICCOSE shall either purchase
the Study Product (or bulk material of API for use therein) from KAYAKU for use in Phase 3 studies conducted by or for EICCOSE at a price [ * ] or at a price set forth below in case of bulk material of API or have it otherwise manufactured pursuant
to the Manufacturing Option under Section 5.3. This purchase or exercise of the Manufacturing Option will be made upon proof of concept in Phase 2 studies and in any event contemporaneously with the Regulatory Authority concurrence on plans for
Phase 3 studies. If EICCOSE elects to source Phase 3 Study Product from KAYAKU, KAYAKU shall sell to EICCOSE the Study Product (or bulk material of API for use therein) to be used for Phase 3 studies. The price per 30 mg of API contained in the
Study Product shall be [ * ]. However, in the event the bulk material of API is supplied in lieu of the Study Product, the price per 30 mg shall be [ * ]. 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 10 of 29 

 (h) Phase 2b and Phase 3 studies to be conducted by EICCOSE under this Agreement are
contemplated to be placebo-controlled studies, so placebo capsules must be used. EICCOSE and KAYAKU shall discuss which Party shall procure or produce placebo capsules, and KAYAKU shall disclose to EICCOSE Information relating to the production of
such placebo capsules to the extent then available if KAYAKU is not the supplier. 
 3.2 Purchase of Study Product by EICCOSE’s
Sublicensees. EICCOSE’s sublicensees shall have the same right to purchase from KAYAKU the Study Product (or bulk material of API for use therein) under the same conditions as in Section 3.1(e), (f) and (g) and under the
conditions of the Supply Agreement and the same Manufacturing Option under Section 5.3. 
 3.3 Development by KAYAKU. 

 (a) KAYAKU or its sublicensees shall conduct development of the Product in the KAYAKU Territory in accordance with the
development plan, which will be provided to EICCOSE by KAYAKU within [ * ] after EICCOSE reports to KAYAKU the results, which may be in the form of a clinical study report, of the Phase 2 studies conducted in the EICCOSE Territory. KAYAKU and
EICCOSE shall discuss such development plan and must reach agreement thereon within [ * ] after receipt by KAYAKU from EICCOSE of such Phase 2 studies report. KAYAKU shall not sublicense its rights under this Agreement until EICCOSE agrees to such
development plan, which agreement shall not be unreasonably withheld. KAYAKU may update and amend the then-current development plan with EICCOSE’s advance written consent, which shall not be unreasonably withheld. KAYAKU shall provide EICCOSE
with a written report on the status and progress of development activities on a [ * ] basis after initiation of clinical development. 

(b) KAYAKU or its sublicensees shall undertake and be responsible for all development, including without limitation, clinical
development of the Product in the KAYAKU Territory. 
 (c) All Information generated in the development activities hereunder by or for
KAYAKU or its sublicensees shall be the property of KAYAKU, its sublicensees, and/or its or their collaborators. In the event such Information is made by such sublicensees, KAYAKU shall ensure that such Information and Patents for inventions in such
Information are included in the Know-How and the Patents owned or Controlled by its sublicensees and can be used by EICCOSE or its sublicensees under the license granted pursuant to Section 2.1(a). In the event such Information is made by such
collaborators, KAYAKU shall, and shall cause its sublicensees to, make reasonable best efforts to own or Control such Information and Patents for inventions in such Information so that such Information and Patents are included in the Know-How and
the Patents owned or Controlled by KAYAKU or its sublicensees as the case may be and can be used by EICCOSE or its sublicensees under the license granted pursuant to Section 2.1(a). 

3.4 Assistance. Upon the other Party’s request, each Party shall, and shall cause its sublicensees to, provide the other Party and
its sublicensees with reasonable assistance in connection with the development of the Product hereunder by the other Party or its sublicensees. 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 11 of 29 

 3.5 Reports. Each Party shall, and shall cause its sublicensees to, document all
preclinical studies and clinical trials conducted by or for it or them in written study reports and shall provide the other Party with a summary of each such report in English promptly after its completion. 

3.6 Disclosure. Each Party shall promptly provide the other Party with (i) such data and information obtained by the development
activities hereunder (including clinical studies and other studies) conducted by, for, on behalf of or in collaboration with such Party or its sublicensees, and (ii) copies of regulatory documents filed in connection with the development
hereunder by or for such Party or its sublicensees, as is reasonably necessary or helpful to the other Party or its sublicensees in obtaining Regulatory Approval for use or sale of the Product in the Field in such other Party’s Territory. 

3.7 Records. Each Party shall maintain complete, current, and accurate records of all work of development conducted by it, and all
Information resulting from such work. Each Party shall cause the sublicensees to maintain complete, current, and accurate records of all work of development conducted by such sublicensees, and all Information resulting from such work. Such records
shall fully and properly reflect all work done and results achieved in the performance of the development activities in good scientific manner appropriate for regulatory purposes. The other Party shall have the right to review all records maintained
by such Party or such sublicensees at reasonable times, upon the other Party’s written request. 
 3.8 Termination of
Development. In the event either Party or its sublicensees determine at its or their sole discretion that further development of the Product by such Party or its sublicensees is commercially, financially, or otherwise not advisable or reasonable
due to the reasons of (i) efficacy, (ii) safety, (iii) infringement of the Third Party’s patent or other intellectual property, or (iv) marketability or profitability, such Party and its sublicensees may terminate the
development of the Product hereunder. In the event such Party (and its sublicensees, if any) have determined to terminate any and all of the development in certain country(ies) in such Party’s Territory, (a) such Party shall promptly give
to the other Party written notice to that effect stating the date of termination of such development, (b) the license granted to such Party (including the sublicenses granted to such sublicensees) pursuant to Section 2.1(a) or 2.2(a), as
applicable, shall terminate on such date with respect to such country(ies), (c) the other Party and its sublicensees shall have access to and the right to use all documents, data, results and other Information generated from or obtained by the
development in such country(ies) hereunder by such Party or its sublicensees and (d) such Party shall, and shall cause its sublicensees to, cooperate with the other Party and its sublicensees for such access and right to use. 

ARTICLE 4  REGULATORY MATTERS 

4.1 Regulatory Responsibilities. 

(a) Subject to Section 2.1(e), which obligates KAYAKU to file and maintain DMFs for the Product in the EICCOSE Territory, each
Party or its sublicensees shall own all 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 12 of 29 

 
Regulatory Filings and Regulatory Approvals for the Product in its Territory, and shall be solely responsible for preparing any and all Regulatory Filings for the Product in its Territory. Each
Party shall assist the other Party or its sublicensees as they may reasonably request in connection with the preparation and filing of such Regulatory Filings and discussions with any Regulatory Authority, to the extent agreed by the Parties, at the
other Party’s or its sublicensees’ reasonable request. 
 (b) Each Party shall keep the other Party informed of regulatory
developments specific to the Product throughout such Party’s Territory. 
 (c) Each Party shall, and shall ensure that its
sublicensees will, be responsible to ensure, at its sole expense, that the development, manufacture, and commercialization of the Product in its Territory are in compliance with all applicable Laws, including without limitation all rules and
regulations promulgated by any of the Regulatory Authorities in its Territory. Specifically and without limiting the foregoing, each Party shall, and shall ensure that its sublicensees will, file all compliance filings, certificates, and safety
reporting in its Territory at its sole expense. 
 4.2 Adverse Events. 

(a) The Parties shall keep each other informed on all reports, including publications of adverse events, coming to either Party’s
knowledge with regard to the Product, regardless of the origin of such reports. 
 (b) Each Party shall report all serious adverse
events occurring in clinical trials under the use of the Product to the other Party within [ * ] after they come to the attention of that Party. In the event of fatal or life-threatening situations, adverse events will be reported to the other Party
within [ * ] by facsimile or email message. 
 (c) The Parties will conclude a separate agreement with respect to the exchange of
safety information, if necessary. 
 4.3 Data Exchange and Use. Each Party shall promptly permit the other Party to access, and shall
provide the other Party with rights to reference and use in association with the Product in the Field for use in their respective Territories, all of its or its sublicensees’ regulatory, preclinical, and clinical data documentation, the
Regulatory Filings, and the Regulatory Approvals with respect to the Product in the Field for use in their respective Territories. 
 ARTICLE
5  COMMERCIALIZATION 
 5.1 Responsibility. Each Party shall be solely responsible for all aspects of the commercialization
by such Party or its sublicensees of the Product in the Field in its Territory. 
 5.2 Trademark. EICCOSE and KAYAKU shall discuss the
use of same trademarks with respect to the commercialization of the Product in the Field. 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 13 of 29 

 5.3 Product; Manufacturing Option. Unless EICCOSE or its sublicensees have exercised their
Manufacturing Option as provided in this Section 5.3, EICCOSE and its sublicensees shall purchase from KAYAKU such quantities of the Product (or bulk material of API for use therein) needed for EICCOSE or its sublicensees, as applicable, in
accordance with the terms and conditions of the Supply Agreement, so long as KAYAKU is able to supply such Product or bulk material of API, at a price of [ * ]. However, in the event the bulk material of API is supplied, the price per 30 mg shall be
[ * ]. Such price shall be on an FCA Japan (INCOTERMS 2010) basis. The Supply Agreement shall provide that KAYAKU shall make the Product (or bulk material of API for use therein) in compliance with all applicable regulatory requirements and Laws in
the EICCOSE Territory. At any time after the successful completion of Phase 2 studies, EICCOSE or its sublicensees shall, however, be free to exercise the Manufacturing Option to source the Product for Phase 3 studies and/or commercial sale (or bulk
material of API for use therein) as they in their sole discretion elect upon notice to KAYAKU. In the case of such notice, KAYAKU shall provide EICCOSE with all Information relating to the manufacture of the API for use by such Third Party
manufacturing source solely for the manufacture of API for or on behalf of EICCOSE or its sublicensees hereunder, which Information shall then become Know-How under Section 1.11, and shall diligently transfer the Manufacturing Know-How to
EICCOSE or its sublicensee or such Third Party, at EICCOSE’s or its sublicensees’ direction and sole expense. KAYAKU estimates the cost of technology transfer of the Manufacturing Know-How shall not exceed [ * ], excluding EICCOSE’s
labor costs, the cost of necessary raw materials, and the costs of the necessary equipment and expenses of operations. In the event EICCOSE or its sublicensees sell the Product which is manufactured by EICCOSE, its sublicensees and/or other Third
Party using Manufacturing Know-How disclosed by KAYAKU as a result of exercising its Manufacturing Option, EICCOSE shall, and shall cause such sublicensees to, pay to KAYAKU a royalty of [ * ] on Net Sales by EICCOSE or its sublicensees of such
Product in the EICCOSE Territory or a lump sum payment agreed by EICCOSE or its sublicensees and KAYAKU, for use of the Manufacturing Know-How. 

5.4 Termination of Commercialization. In the event either Party or its sublicensees determine at its or their sole discretion that
further commercial sale of the Product by such Party or its sublicensees are commercially, financially, or otherwise not advisable or reasonable due to the reasons of (i) efficacy, (ii) safety, (iii) infringement of the Third
Party’s patent or other intellectual property, (iv) marketability, or (v) profitability, such Party and its sublicensees may terminate the commercial sale of the Product. In the event such Party (and its sublicensees, if any) has
determined to terminate any and all of the commercial sale of the Product in certain country(ies) in such Party’s Territory, (a) such Party shall promptly give to the other Party [ * ] written notice to that effect stating the date of
termination of such commercial sale, (b) the license granted to such Party (including the sublicenses granted to such sublicensees) pursuant to Section 2.1(a) or 2.2(a) as applicable shall terminate on such date with respect to such
country(ies), (c) the other Party and its sublicensees may have access to and the right to use all documents, data, results and other Information generated from or obtained by the development and the commercial sale in such country(ies)
hereunder by such Party or its sublicensees and (d) such Party shall, and shall cause its sublicensees to, cooperate with the other Party and its sublicensees for such access and right to use. 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 14 of 29 

 ARTICLE 6  PAYMENT 

6.1 Running Royalties. For the grant of license to KAYAKU pursuant to Section 2.2(a), KAYAKU shall, during the Royalty Term, pay to
EICCOSE the running royalty on sales by KAYAKU or its sublicensees of the Product for use in the Field in the KAYAKU Territory at a rate of [ * ] of the Net Sales as follows: 

(a) Royalty Term. The running royalty payment obligation under Section 2.2 (a) shall be due, on a country-by-country basis,
during the period of time beginning upon the First Commercial Sale of the Product in such country, and ending upon the later of (i) the date of expiration of the last-to-expire Valid Claim covering the Product or its use, manufacture, or sale
in such country, and (ii) the tenth (10th) anniversary after the First Commercial Sale of the Product in such country (the “Royalty Term”). 

(b) Royalty Payments and Reports. KAYAKU shall deliver to EICCOSE a report containing the following information for the prior calendar
quarter: (i) the number, description, and aggregate Net Sales of licensed Product during the completed calendar quarter; (ii) the gross sales associated with the Product sold by KAYAKU and its sublicensees; (iii) a calculation of the
Net Sales of the Product sold by KAYAKU or its sublicensees; and (iv) a calculation of payments due to EICCOSE with respect to the foregoing. KAYAKU shall deliver the foregoing report to EICCOSE within [ * ] after the end of such calendar
quarter. Within [ * ] after the end of each calendar quarter, KAYAKU shall remit to EICCOSE any payment due for the applicable calendar quarter in U.S. dollars. If no royalties are due to EICCOSE for such reporting period, the report shall so state.
In the event KAYAKU has Net Sales of Product for which a royalty payment by EICCOSE is due under the Stanford License, it being understood that no such royalty is due for Product made and sold in the Asian Territory, then KAYAKU shall comply with
the royalty reporting obligations contained therein for such Net Sales. 
 (c) Foreign Exchange. The rate of exchange to be used in
computing the amount of currency equivalent in U.S. dollars of the Net Sales invoiced in other currencies shall be made at the average of the closing exchange rates (TTM) reported by The Bank of Tokyo-Mitsubishi UFJ, Ltd. over the last five
(5) business days of the applicable reporting period for the payment due. 
 (d) Payment Method; Late Payments. All royalty
payments due to EICCOSE hereunder shall be made by wire transfer of immediately available funds into an account designated by EICCOSE. If EICCOSE does not receive payment of any sum due to it on or before the due date, simple interest shall
thereafter accrue on the sum due to EICCOSE until the date of payment at the per annum rate of [ * ] over the then-current prime rate reported by The Bank of Tokyo-Mitsubishi UFJ, Ltd. in Japan or the maximum rate allowable by applicable Law,
whichever is lower. 
 6.2 Records; Audits. KAYAKU will, and will assure that its sublicensees will, maintain complete and accurate
records in sufficient detail to permit EICCOSE to confirm the 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 15 of 29 

 
accuracy of the calculation of running royalty payments under this Agreement. Upon reasonable prior notice, such records shall be available during regular business hours for a period of [ * ]
from the end of the calendar year to which they pertain for examination at the expense of EICCOSE, and not more often than [ * ] each calendar year, by an independent certified public accountant selected by EICCOSE and reasonably acceptable to
KAYAKU or its sublicensees, for the sole purpose of verifying the accuracy of the financial reports furnished by KAYAKU pursuant to this Agreement. Any such auditor shall not disclose to EICCOSE KAYAKU’s Confidential Information or its
sublicensees’ Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by KAYAKU or the amount of payments due by KAYAKU under this Agreement. Any amounts shown to be
owed but unpaid shall be paid within [ * ] from the receipt by KAYAKU of the accountant’s report, plus interest (as set forth in Section 6.1(d)) from the original due date. 

6.3 Taxes. The Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate tax withholding or similar
obligations in respect of the running royalty. In the event that KAYAKU is required to withhold any taxes on any amount payable to EICCOSE hereunder, under the applicable Laws of the KAYAKU Territory, KAYAKU may deduct such withholding taxes and
shall obtain and furnish EICCOSE with official tax receipts, or other evidence of payment of such withholding taxes, sufficient to permit EICCOSE to demonstrate the payment of such withholding taxes, in order to establish EICCOSE’s right to a
credit for such withholding taxes against EICCOSE’s income tax liability in U.S. 
 6.4 Costs for DMF, etc. EICCOSE shall bear
the direct costs incurred by KAYAKU for preparing documents necessary for EICCOSE to file application for conducting clinical development and obtaining Regulatory Approval, including the DMF, in the EICCOSE Territory and shall pay to KAYAKU [ * ]
for the same. EICCOSE shall pay to KAYAKU, by telegraphic transfer to the bank account designated by KAYAKU, [ * ] after receipt of invoice to be issued by KAYAKU after the Effective Date. EICCOSE shall pay to KAYAKU remaining [ * ] after such
documents have been prepared, filed, and determined adequate by the Regulatory Authority, at which time KAYAKU shall issue an invoice that shall be paid by EICCOSE within [ * ] by telegraphic transfer to the bank account designated by KAYAKU. In the
event, such documents are finally determined not adequate by the Regulatory Authority due to the reasons attributable to KAYAKU, KAYAKU shall pay back to EICCOSE such [ * ] received from EICCOSE. However, in the event, such documents are finally
determined not adequate by the Regulatory Authority due to the reasons not attributable to KAYAKU, KAYAKU shall not pay back to EICCOSE such [ * ] and EICCOSE shall pay to KAYAKU such [ * ] after receipt of invoice from KAYAKU. 

ARTICLE 7  INTELLECTUAL PROPERTY 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 16 of 29 

 7.1 Infringement of Patents by Third Parties. 

(a) Notification. Each Party shall promptly notify the other Party in writing of any existing or threatened infringement of the Patents
owned or Controlled by such Party or the other Party or their sublicensees through the development or commercialization of the Product in the Field by any Third Party, of which such Party becomes aware. 

(b) Product Infringement. In the event a Party’s Patents are infringed by the commercialization of the Product in the Field by a
Third Party in the other Party’s Territory, such Party shall make reasonable efforts to stop such infringement in the other Party’s Territory to protect the commercialization of the Product in the Field by the other Party or its
sublicensees in the other Party’s Territory. If such Party fails to institute and prosecute an action or proceeding to remove such infringement without delay, then the other Party shall have the right, but not the obligation to, commence a suit
or take action to enforce the applicable Patents against such Third Party perpetrating such infringement in the other Party’s Territory at its own cost and expense. In this case, such Party shall take appropriate actions, if any, to enable the
other Party to commence a suit or take the actions set forth in the preceding sentence. 
 7.2 Infringement of Third Party Rights.
Each Party shall not be liable for the infringement of patents or other intellectual property rights of a Third Party by the commercialization of the Product or any other activities under this Agreement by the other Party or its sublicensees. 

ARTICLE 8  REPRESENTATIONS AND WARRANTIES 

8.1 Mutual Representations and Warranties. Each Party hereby represents, warrants, and covenants (as applicable) to the other Party as
follows: 
 (a) Authority and Binding Agreement. As of the Effective Date, (i) it has the corporate power and authority
and the legal right to enter into this Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of its
obligations hereunder; and (iii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms.

 (b) No Conflict; Covenant. It is not a party to any agreement that would materially prevent it from granting the rights granted
to the other Party under this Agreement or performing its obligations under this Agreement. 
 (c) No Notice of Infringement.
As of the Effective Date, each Party has not received any written notice from any Third Party asserting or alleging that any development or commercialization of a Product in the Field by such Party infringes or misappropriates the intellectual
property rights of such Third Party. 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 17 of 29 

 (d) No Debarment. In the course of the development of the Product, each Party shall not
use, during the Term, any employee or consultant who has been debarred by any Regulatory Authority, or, to the best of such Party’s knowledge, is the subject of debarment proceedings by the Regulatory Authority. 

8.2 No Other Representations or Warranties. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER,
WHETHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, IS MADE OR GIVEN BY OR ON BEHALF OF THE PARTY. ALL REPRESENTATIONS AND WARRANTIES OTHER THAN THOSE EXPRESSLY STATED IN THIS
AGREEMENT, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. 
 ARTICLE 9  INDEMNIFICATION 

9.1 Indemnification. Each Party hereby agrees to defend, hold harmless, and indemnify the other Party from and against any and all
liabilities, damages, expenses, and/or losses, including without limitation reasonable legal expenses and attorneys’ fees (collectively “Losses”), in each case resulting from any Third Party suits, claims, actions, and demands
arising directly or indirectly out of (a) a breach of any of such Party’s obligations under this Agreement, or (b) the negligence or willful misconduct of such Party. Such Party’s obligation shall not apply to the extent that any
such Losses arise from: (A) the negligence or willful misconduct of the other Party, or (B) the other Party’s breach of this Agreement. 

9.2 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, INCIDENTAL, PUNITIVE, INDIRECT, OR
CONSEQUENTIAL DAMAGES OR LOSS OF PROFITS INCURRED BY EITHER PARTY AND ARISING FROM PERFORMANCE OR NON-PERFPRMANCE UNDER THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES, EXCEPT WHEN SUCH LIABILITY ARISES FROM SUCH
PARTY’S INTENTIONAL BREACH OF OR WILLFUL MISCONDUCT, IN WHICH CASE THERE SHALL BE NO LIMIT TO SUCH LIABILITY. 
 ARTICLE 10  CONFIDENTIALITY

 10.1 Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the
Parties, each Party agrees that it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of
any obligations hereunder) any Confidential Information received from the other Party under this Agreement. 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 18 of 29 

 
The foregoing confidentiality and non-use obligations shall not apply to any portion of the Confidential Information that the receiving Party can demonstrate by competent written proof: 

(a) was already known to the receiving Party or its Affiliate, other than under an obligation of confidentiality, at the time of
disclosure by the other Party; 
 (b) was generally available to the public or otherwise part of the public domain at the time
of its disclosure to the receiving Party; 
 (c) became generally available to the public or otherwise part of the public
domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 
 (d)
is subsequently disclosed to the receiving Party or its Affiliate by the Third Party who has a legal right to make such disclosure; or 

(e) is subsequently independently discovered or developed by the receiving Party or its Affiliate without the aid, application, or use
of the Confidential Information received from the disclosing Party, as evidenced by a contemporaneous writing. 
 10.2 Authorized
Disclosure. Notwithstanding the obligations set forth in Section 10.1, the Party may disclose the Confidential Information received from the other Party to the extent: 

(a) such disclosure: (i) is reasonably necessary for the prosecuting or defending litigation as contemplated by this Agreement, or
(ii) reasonably necessary for a Regulatory Filing or Regulatory Approval; 
 (b) such disclosure is reasonably necessary:
(i) to such Party’s attorneys, independent accountants, or advisors for the sole purpose of enabling such attorneys, independent accountants, or advisors to provide advice to the receiving Party, provided that in each such case on the
condition that such attorneys, independent accountants, and advisors are bound by confidentiality and non-use obligations consistent with those contained in this Agreement; or (ii) to actual or potential investors and/or acquirers solely for
the purpose of evaluating an actual or potential investment or acquisition, provided that in each such case on the condition that such actual or potential investors and/or acquirers are bound by confidentiality and non-use obligations consistent
with those contained in this Agreement;  
 (c) such disclosure is required by judicial or administrative process, provided
that in such event such Party shall promptly inform the other Party of such required disclosure and provide the other Party an opportunity to challenge or limit the disclosure obligations; the Confidential Information that is disclosed by judicial
or administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this Article 10, and the Party disclosing the Confidential Information pursuant to law or court order shall take all steps reasonably
necessary, including seeking of confidential treatment or a protective order to ensure the continued confidential treatment of such Confidential Information; 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 19 of 29 

 (d) such disclosure is reasonably necessary to its collaborators in its respective
Territory (including CROs, hospitals, doctors, consultants, subcontractors, and the Affiliates) for the purpose of the development, manufacture, and/or commercialization of the Product or API as applicable, solely for the purpose of carrying out
such collaboration, on the condition that such collaborators are bound by confidentiality and non-use obligations consistent with those contained in Section 10.1 for a period of at least [ * ] after the disclosure of the Confidential
Information to such collaborators; for clarity, each Party shall have the right to disclose to its sublicensees in its Territory, and such sublicensees shall have the right to use, the Confidential Information received from the other Party in
accordance with the right granted under the sublicense under Section 2.1(a) or Section 2.2(a) on condition that such sublicensees are bound by confidentiality and non-use obligations consistent with those contained in this Agreement; or

 (e) such disclosure is reasonably necessary to its potential sublicensees to have such potential sublicensees evaluate the
possibility of sublicenses under Section 2.1(a) or 2.2(a) on condition that such potential sublicensees are bound by confidentiality and non-use obligations consistent with those contained in Section 10.1 for a period of at least [ * ]
after the disclosure of the Confidential Information to such potential sublicensees. 
 10.3  Other Disclosure. 

(a) During the Term, each Party shall have the right to issue press release or make a public announcement concerning the material terms
of this Agreement or the development or commercialization of the Product under this Agreement, such as announcing the commencement and completion of clinical studies for the Product in its Territory, the filing and obtaining of the Regulatory
Approvals for the Product in its Territory, the First Commercial Sale of the Product in its Territory, after providing the other Party with reasonable advance notice of the content thereof. Such other Party shall have the right to review and comment
on such proposed press release or announcement and the Party seeking such disclosure shall take into consideration and incorporate when appropriate the comment from the other Party. 

(b) The Parties agree that each Party and its sublicensees may publish or disclose any data, results and other Information generated
from or obtained by the development hereunder by such Party or its sublicensees, but only after such Information has been disclosed to the other Party, but each Party and its sublicensees shall not publish or disclose any data, results and other
Information generated from or obtained by the development hereunder by the other Party or its sublicensees without prior written consent of the other Party. 

10.4 Equitable Relief. Each Party acknowledges that a breach of this Article 10 may not reasonably or adequately be compensated in
damages in an action at law and that such a breach could cause the other Party irreparable injury and damage. By reason thereof, each Party agrees that the other Party shall be entitled, in addition to any other remedies it may have under this
Agreement or otherwise, to preliminary and permanent injunctive and other equitable relief to prevent or curtail any breach of the obligations relating to the Confidential Information set forth herein by such Party.  

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 20 of 29 

 10.5 Obligation Period. Except as otherwise provided for herein, the obligations of the
Parties under this Article 10 shall continue for a period of [ * ] after the expiration or termination of this Agreement. 
 ARTICLE 11  TERM AND
TERMINATION 
 11.1 Term. This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to
this Article 11, shall remain in effect so long as any of EICCOSE, KAYAKU or their sublicensees intends to conduct or is conducting development or sale of the Product in the Field (“Term”). 

11.2 Termination for Breach or for Other Reasons. 

(a) Notice. If either Party believes that the other Party is in material breach of this Agreement, then the Party holding such belief
(the “Non-breaching Party”) may deliver notice of such breach to the other Party (the “Notified Party”). The Notified Party shall have [ * ] to cure such breach, if such breach exists, to the extent involving
non-payment of amounts due hereunder or failure to deliver material quantities of Product meeting applicable specifications in a timely manner, and [ * ] either to cure such breach for all other material breaches, or, if cure of such breach other
than non-payment cannot reasonably be effected within such [ * ] period, to deliver to the Non-breaching Party a plan reasonably calculated to cure such breach within a timeframe that is reasonably prompt in light of the circumstances then
prevailing but in no event longer than an additional [ * ]. Following delivery of such a plan, the Notified Party shall carry out the plan and cure the breach within the timeframe set forth in the plan, and the failure of the Notified Party to cure
the breach within such timeframe shall result in the immediate and automatic termination of this Agreement upon the expiration of such timeframe.  

(b) Failure to Cure. If the Notified Party fails to cure a material breach of this Agreement as provided for in Section 11.2(a),
then the Non-Breaching Party may terminate this Agreement upon written notice to the Notified Party. 
 (c) Termination by
KAYAKU. KAYAKU may terminate this Agreement immediately upon written notice to EICCOSE if (i) EICCOSE or its sublicensee has not filed a Regulatory Filing (e.g., an Investigational New Drug application filed with the FDA contemplating
Phase 2 studies) under this Agreement within twelve (12) months of the Effective Date, (ii) after making such a Regulatory Filing under this Agreement, EICCOSE or its sublicensee does not conduct development activities under this
Agreement for a period of fifteen (15) months, (iii) EICCOSE or its sublicensee does not file an application for Regulatory Approval under this Agreement within [ * ] after the Effective Date, (iv) EICCOSE or its sublicensee does not
obtain Regulatory Approval under this Agreement within [ * ] after the Effective Date, (v) EICCOSE or its sublicensee ceases development or commercialization of the Product under this Agreement, or (vi) EICCOSE or its sublicensee initiates
development of the Product in the Field in the EICCOSE Territory other than under this Agreement. 
 (d) Termination by agreement. In
the event all of EICCOSE, KAYAKU, and their respective sublicensees hereunder, if any, agree that further development or commercialization of the Product hereunder is commercially, financially, or otherwise not advisable, the Parties shall terminate
this Agreement. 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 21 of 29 

 11.3 Rights upon Termination of this Agreement. In the event this Agreement is terminated
pursuant to Section 11.2, upon termination of this Agreement, each Party shall immediately return and destroy all documents, in written and electronic form, containing the Confidential Information received from the other Party and destroy any
copies of such Confidential Information and notes containing such Confidential Information, except that each Party may retain one copy of such documents for record keeping purposes only in a safe and secure place; provided, however, that Information
that has to be stored or archived according to GLP-Regulations may be so stored without breach of this Section 11.3. 
 11.4
Survival. Termination or expiration of this Agreement shall not operate to release any Party from (i) any obligation that may survive expiration or termination of this Agreement as expressly stated herein, (ii) any obligations which by
implication are intended to come into or continue in force on or after expiration or termination of this Agreement, and (iii) liability incurred under the terms of this Agreement prior to or upon expiration or termination of this Agreement.

 ARTICLE 12  MISCELLANEOUS 

12.1 Entire Agreement; Amendment. This Agreement, including the Appendix and the Exhibits hereto, sets forth the complete, final, and
exclusive agreement, and all the covenants, promises, agreements, warranties, representations, conditions, and understandings between the Parties with respect to the subject matter hereof, and supersedes, as of the Effective Date, all prior
agreements and understandings between the Parties with respect to the subject matter hereof. There are no covenants, promises, agreements, warranties, representations, conditions, or understandings, either oral or written, between the Parties other
than as are set forth herein. No subsequent alteration, amendment, change, or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized representative of each Party. 

12.2 Force Majeure. Each Party shall be excused from the performance of its obligations under this Agreement to the extent that such
performance is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued so long as the condition constituting force majeure continues and the nonperforming
Party takes reasonable efforts to remove the condition. For purposes of this Agreement, force majeure shall include conditions beyond the reasonable control of the nonperforming Party, including without limitation, an act of God, terrorism,
involuntary compliance with any regulation, law, or order of any government, war, civil commotion, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm, or
like catastrophe, and such catastrophes generally. Notwithstanding the foregoing, if KAYAKU is unable to supply Study Product or Product due to force majeure, then it shall notify EICCOSE of that inability as promptly as possible, and EICCOSE shall
have the right to exercise its Manufacturing Right under Section 5.3 immediately (regardless of whether Phase 2 studies have then been successfully completed). Otherwise, a Party shall not be excused from making payments owed hereunder because
of a force majeure affecting such Party. If a force majeure persists for more than ninety (90) days, then the Parties will 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 22 of 29 

 
discuss in good faith the modification of the Parties’ obligations under this Agreement to mitigate any delays caused by such force majeure. 

12.3 Dispute Resolution. If any dispute or difference arises out of or in connection with this Agreement between the Parties, such
dispute or difference shall be settled amicably by mutual discussion if practicable, within [ * ] of written notification of a dispute or difference. In case of failure of amicable settlement within such [ * ] period, it shall be finally settled by
arbitration conducted in the English language in accordance with the Rules of Arbitration of the International Chamber of Commerce. The arbitration shall be held in Tokyo, Japan, if KAYAKU is defendant, and in San Francisco, California, if EICCOSE
is defendant. The award thereof shall be final and binding upon the Parties, and judgment on such award may be entered in any court or tribunal having jurisdiction thereof. 

12.4 Notices. Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this
Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section 12.4, and shall be deemed to have been given for all
purposes (a) when received, if hand-delivered or sent by confirmed facsimile or a reputable courier service, or (b) seven (7) business days after mailing, if mailed by first class certified or registered airmail, postage prepaid,
return receipt requested. 
  

					
		 	If to KAYAKU:	  	Nippon Kayaku Co., Ltd.
		 		  	1-1, Marunouchi 2-chome, Chiyoda-ku
		 		  	Tokyo 100-0005, Japan
		 		  	Attention: Head of Business Development Division
		 		  	Facsimile: +81-50-3730-6898
			
		 	If to EICCOSE:	  	Eiccose Pharmaceuticals Inc.
		 		  	1115 Lafayette St., Santa Clara
		 		  	CA 95050, USA
		 		  	Attention: Chief Executive Officer
		 		  	Email: DCory@eiccose.com

 12.5 Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations
hereunder without the prior written consent of the other Party, except that the Party may make such an assignment without the other Party’s consent to a successor to substantially all of the business of such Party to which this Agreement
relates (whether by merger, acquisition, sale of stock, sale of assets, or other transaction). Any permitted assignment shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of
the terms of this Section 12.5 shall be null, void, and of no legal effect. Upon any such assignment or acquisition, any reference herein to “EICCOSE” shall mean the assignee or acquirer, as the case may be. 

12.6 Severability. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of
competent jurisdiction from which no appeal can be or is  

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 23 of 29 

 
taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace any
invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

12.7 No Waiver. Any delay in enforcing the Party’s rights under this Agreement or any waiver as to a particular default or other
matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, except with respect to an express written and signed waiver relating to a particular matter for a particular period of
time. 
 12.8 Independent Contractors. Each Party shall act solely as an independent contractor, and nothing in this Agreement
shall be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way. Nothing herein shall be construed to create the relationship of partners, principal and agent, or joint-venture partners between
the Parties. 
 12.9 Governing Law. This Agreement and all disputes arising out of or related to this Agreement or any breach
hereof shall be governed by and construed under the laws of the state of Delaware of the United States, without giving effect to any choice of law principles that would require the application of the laws of a different state. 

12.10 Counterparts. This Agreement shall be executed in two (2) counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. 
 IN WITNESS
WHEREOF, the Parties have executed this Agreement in English language in duplicate originals by their duly authorized representatives as of the Effective Date. 

 

							
				
	NIPPON KAYAKU CO., LTD.	 		 		 	EICCOSE PHARMACEUTICALS, INC.
				
	By: /s/ Masanobu Suzuki                                
                        	 		 		 	By:/s/ David Cory                                 
                                   
	Name: Masanobu Suzuki	 		 		 	Name: David Cory 
	Title: Senior Managing Director	 		 		 	Title: President and CEO 
				
	        Head of Pharmaceuticals Group	 		 		 	
				
	Date: April 27, 2015	 		 		 	Date: May 1, 2015

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 24 of 29 

 Appendix 2.2(g) 

As required under the Stanford License, KAYAKU and its sublicensees acknowledge and agree that the license grant under Section 2.2
(a) of this Agreement is further subject to the following, for the benefit of Stanford: 
 (1) No Refund for Patent Challenge. In
the event that a validity or non-infringement challenge of a patent sublicensed from Stanford is brought by KAYAKU or a KAYAKU sublicensee, and the challenge is successful, KAYAKU will have no right to recoup any royalties paid before or during the
period of such challenge. 
 (2) Termination Report. KAYAKU will, even after the termination of the Stanford License, pay to EICCOSE
the running royalty set forth in Section 2.2(a) and submit to EICCOSE a report set forth in Section 6.1 (b) pursuant to Section 6.1 (b). EICCOSE shall inform KAYAKU of the termination date of the Stanford License. 

(3) Accounting. KAYAKU and its sublicensees will maintain records showing manufacture, importation, sale, and use of Product for [ * ]
from the date of sale of the Product. Records will include general-ledger records showing accruals and cash receipts and expenses, and records that include related information in sufficient detail to enable EICCOSE and Stanford to determine the
royalties payable under this Agreement. 
 (4) Audit. KAYAKU and its sublicensees will allow an independent certified public
accountant of EICCOSE or Stanford reasonably acceptable to KAYAKU or its sublicensees to examine KAYAKU’s and its sublicensee’s records to verify payments made by KAYAKU under this Agreement. EICCOSE or Stanford will pay for any audit
done, but if the audit reveals an underreporting of earned royalties due EICCOSE of [ * ] or more for the period being audited, KAYAKU will pay the audit costs. 

(5) Negation of Warranties. Stanford has provided EICCOSE the rights and licenses granted in the Stanford License “AS IS” and
“WITH ALL FAULTS”. Stanford makes no representations and extends no warranties of any kind, either express or implied with respect to the Stanford Sublicense. Among other things, Stanford disclaims any express or implied warranty: of
merchantability, of fitness for a particular purpose, of non-infringement or arising out of any course of dealing.  

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 25 of 29 

 (6) No Representation of Licensed Patent. KAYAKU also acknowledges that Stanford does not
represent or warrant with respect to the Stanford Sublicense: the validity or scope of any patent licensed to EICCOSE, or that the exploitation of any patent licensed from Stanford will be successful. 

(7) Indemnification. KAYAKU will indemnify, hold harmless, and defend all the United States Department of Veterans Affairs, Stanford,
and Stanford Hospitals and Clinics, and their respective trustees, officers, employees, students, and agents against any claim of any kind arising out of or related to the exercise of any rights granted by EICCOSE under the Stanford Sublicense or
the breach of this Agreement by KAYAKU.  
 (8) No Indirect Liability. Stanford is not liable for any special, consequential,
lost profit, expectation, punitive, or other indirect damages in connection with any claim arising out of or related to this Agreement (including the Stanford Sublicense), whether grounded in tort (including negligence), strict liability, contract,
or otherwise.  
 (9) Workers’ Compensation. KAYAKU will comply with all statutory workers’ compensation and
employers’ liability requirements for activities performed by workers or employees of KAYAKU under this Agreement. 
 (10)
Insurance. KAYAKU and its sublicensees shall procure and maintain insurance, including product liability insurance, adequate to cover their respective obligations hereunder and which are consistent with normal business practices of prudent
companies similarly situated at all times during which the Product is being clinically tested in human subjects or commercially distributed or sold by KAYAKU or its sublicensees, as applicable. 

(11) Litigation by KAYAKU. In the event KAYAKU or a KAYAKU sublicensee brings an action seeking to invalidate any patent sublicensed
from Stanford under the Stanford Sublicense: KAYAKU will [ * ] the payment of the running royalty paid to EICCOSE on the sales of the Product in the country where such action to invalidate such patent is sought, during the pendency of such action
and EICCOSE shall pay such amounts to Stanford as required under the Stanford License with respect to the KAYAUK Territory. Moreover, should the outcome of such action determine that any claim of a patent challenged by KAYAKU is both valid and
infringed by a Product in the 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 26 of 29 

 
Field, KAYAKU will pay [ * ] the running royalty originally due under this Agreement on the sales of the Product in the country where such action to invalidate such patent is sought; KAYAKU and
any KAYAKU sublicensee will have no right to recoup any royalties paid before or during the period of challenge; KAYAKU shall not pay royalties into any escrow or other similar account. KAYAKU will provide written notice to EICCOSE and Stanford at
least [ * ] prior to bringing an action seeking to invalidate a patent sublicensed under the Stanford Sublicense. KAYAKU will include with such written notice an identification of all prior arts it knows at the time of such notice and believes
invalidates any claim of any patent sublicensed under the Stanford Sublicense. 
 (12) License to the US Government. The United States
Government has a nonexclusive, nontransferable, irrevocable, royalty-free, paid-up right to practice or have practiced the patents licensed from Stanford throughout the world by or on behalf of the United States Government and on behalf of any
foreign government or international organization pursuant to any existing or future treaty or agreement to which the United States Government is a signatory. 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 27 of 29 

 Exhibit A 

EICCOSE Development Plan 
 [ * ] 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 28 of 29 

 [ * ] 

  
 [ * ] = Certain confidential information
contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Page 29 of 29ex10-1.htm

Exhibit 10.1

 

AMENDMENT NUMBER FIVE TO AMENDED AND RESTATED BUSINESS FINANCING AGREEMENT

 

This AMENDMENT NUMBER FIVE TO AMENDED AND RESTATED BUSINESS FINANCING AGREEMENT (this “Amendment”), dated as of February 3, 2016, is entered into by and among Western Alliance Bank, an Arizona corporation, as successor in interest to Bridge Bank, National Association (“Lender”), on the one hand, and Determine Inc., a Delaware corporation, f/k/a Selectica, Inc. (“Determine”), and Determine Sourcing, Inc., a Delaware corporation, f/k/a Selectica Sourcing Inc. (“Sourcing,” together with Determine, each a “Borrower,” and collectively “Borrowers”) on the other hand, with reference to the following facts:

 

A.     Borrowers and Lender previously entered into that certain Amended and Restated Business Financing Agreement, dated as of July 25, 2014, as amended by that certain Amendment Number One to Amended and Restated Business Financing Agreement and Waiver of Defaults, dated as of December 31, 2014, that certain Amendment Number Two to Amended and Restated Business Financing Agreement, dated as of March 11, 2015, that certain Amendment Number Three to Amended and Restated Business Financing Agreement, dated as of June 5, 2015, and that certain Amendment Number Four to Amended and Restated Business Financing Agreement and Waiver of Defaults, dated as of November 13, 2015 (as so amended, the “Agreement”). 

 

B.     Borrowers and Lender desire to further amend the Agreement in accordance with the terms and conditions set forth herein.

 

NOW, THEREFORE, in consideration of the foregoing, the parties hereto hereby agree as follows:

 

1.     Defined Terms. All initially capitalized terms used but not defined herein shall have the meanings assigned to such terms in the Agreement.

 

2.     Global Amendments to Agreement. The Agreement is hereby amended to replace all references to Selectica Sourcing Inc., a Delaware corporation, with Determine Sourcing, Inc., a Delaware corporation, f/k/a Selectica Sourcing Inc.

 

3.     Amendment to Section 1.1. Section 1.1 of the Agreement is hereby amended in its entirety as follows:

 

1.1     Advances.

 

	 	
(a)
	
ABL Advances. Subject to the terms and conditions of this Agreement, from the date on which this Agreement becomes effective until the Maturity Date, Lender will make ABL Advances to Borrowers not exceeding the ABL Credit Limit or the Borrowing Base, whichever is less; provided that in no event shall Lender be obligated to make any ABL Advance that results in an Overadvance or while any Overadvance is outstanding.

 

	 	
(b)
	
Cash-Secured Advances. Subject to the terms and conditions of this Agreement, from the date on which this Agreement becomes effective until the Maturity Date, Lender will make Cash-Secured Advances to Borrowers not exceeding the Cash-Secured Credit Limit; provided that in no event shall Lender be obligated to make any Cash-Secured Advance unless the Cash Collateral is on deposit with Lender and subject to Lender’s first priority perfected security interest.

  

 

1

 

 

	 	
(c)
	
Cash-Secured Advances II. Subject to the terms and conditions of this Agreement, from the date on which this Agreement becomes effective until the Cash-Secured Advances II Maturity Date, Lender will make Cash-Secured Advances II to Borrowers not exceeding the Cash-Secured Credit Limit II; provided that in no event shall Lender be obligated to make any Cash-Secured Advance II unless the Cash Collateral II is on deposit with Lender and subject to Lender’s first priority perfected security interest.

 

	 	
(d)
	
Revolving Advances. Amounts borrowed under this Section may be repaid and reborrowed during the term of this Agreement. It shall be a condition to each Advance that (a) an Advance Request acceptable to Lender has been received by Lender, (b) all of the representations and warranties set forth in Section 3 are true and correct on the date of such Advance as though made at and as of each such date, and (c) no Default has occurred and is continuing, or would result from such Advance

 

4.     Amendment to Section 1.7. Section 1.7 of the Agreement is hereby amended in its entirety as follows:

 

	 	
1.7
	
Recourse; Maturity. Advances and the other Obligations shall be with full recourse against Borrowers. On the Maturity Date, Borrowers will pay all then outstanding ABL Advances, Cash-Secured Advances and other Obligations (other than Cash-Secured Advances II) to the Lender or such earlier date as shall be herein provided. On the Cash-Secured Advances II Maturity Date, Borrowers will pay all then outstanding Cash-Secured Advances II and other Obligations to the Lender or such earlier date as shall be herein provided.

 

5.     Amendments to Sections 2.2(a) and (b). Sections 2.2(a) and (b) of the Agreement are hereby amended in their entirety as follows:

 

	 	
(a)
	
Termination Fee. In the event this Agreement is terminated on or before February 3, 2017, Borrowers shall pay Lender the Termination Fee.

 

	 	
(b)
	
Facility Fee. Borrowers shall pay (i) the Facility Fee with respect to the ABL Credit Limit and the Cash Secured Credit Limit to Lender on March 20 of each year, and (ii) the Facility Fee with respect to the Cash Secured Credit Limit II to Lender on February 3 of each year.

 

6.     Amendments to Section 12.1.

 

(a)     The following defined terms set forth in Section 12.1 of the Agreement are hereby amended in their entirety as follows:

 

“Advance” means an ABL Advance, a Cash-Secured Advance, or a Cash-Secured Advance II.

 

“Advance Request” means a writing in form and substance satisfactory to Lender and signed by an Authorized Person requesting either an ABL Advance, a Cash-Secured Advance, or a Cash-Secured Advance II.

 

“Asset Coverage Ratio” means (i) the sum of (a) Borrowers’ unrestricted cash maintained on deposit at Lender (or subject to a control agreement in form and substance reasonably acceptable to Lender in its sole discretion) (excluding proceeds of Cash-Secured Advances) plus (b) Eligible Receivables (as reported on the most recent borrowing base certificate), divided by (ii) the Obligations (excluding Cash-Secured Advances, Cash Secured Advances II, and Advances under the Non-Formula Sublimit).

 

 

2

 

  

“Collateral” means all of each Borrower’s rights and interest in any and all personal property, whether now existing or hereafter acquired or created and wherever located, and all products and proceeds thereof and accessions thereto, including but not limited to the following: (a) all accounts (including health care insurance receivables), chattel paper (including tangible and electronic chattel paper), inventory (including all goods held for sale or lease or to be furnished under a contract for service, and including returns and repossessions), equipment (including all accessions and additions thereto), instruments (including promissory notes), investment property (including securities and securities entitlements), documents (including negotiable documents), deposit accounts, letter of credit rights, money, any commercial tort claim of such Borrower which is now or hereafter identified by Borrowers or Lender, general intangibles (including payment intangibles and software), goods (including fixtures) and all of such Borrower’s books and records with respect to any of the foregoing, and the computers and equipment containing said books and records; (b) the Cash Collateral and the Cash Collateral II, and (c) any and all cash proceeds and/or noncash proceeds thereof, including without limitation, insurance proceeds, and all supporting obligations and the security therefore or for any right to payment.

 

“Credit Limit” means $12,000,000, which is intended to be the maximum amount of Advances at any time outstanding.

 

“Facility Fee” means, (a) with respect to the ABL Credit Limit and the Cash Secured Credit Limit, a payment of an annual fee equal to $67,500 due on March 20 of each year so long us any ABL Advance or Cash Secured Advance is outstanding or available hereunder, and (b) with respect to the Cash Secured Credit Limit II, a payment of an annual fee equal to $22,500 due on February 3 of each year so long us any Cash Secured Advance II is outstanding or available hereunder.

 

“Finance Charge Percentage” means, (a) with respect to all ABL Advances, a rate per year equal to the Prime Rate plus one quarter of one percentage point (0.25), plus an additional 5.00 percentage points during any period that an Event of Default has occurred and is continuing, (b) with respect to all Cash-Secured Advances, a rate per year equal to the CD Rate plus two (2) percentage points, plus an additional 5.00 percentage points during any period that an Event of Default has occurred and is continuing, and (c) with respect to all Cash-Secured Advances II, a rate per year equal to the CD Rate plus two (2) percentage points, plus an additional 5.00 percentage points during any period that an Event of Default has occurred and is continuing.

 

(b)     The following new defined terms are hereby added to Section 12.1 of the Agreement in alphabetical order:

 

“Alliance” means Alliance Semiconductor Corporation, a Delaware corporation.

 

“Cash Collateral II” means the sum of $3,000,000 plus an amount equal to 90 days Finance Charge with respect to the Cash-Secured Advances II (assuming that the full amount of Cash-Secured Advances II available hereunder are outstanding at all times) in cash collateral in which Alliance has granted to Lender a first priority perfected security interest to secure the Cash-Secured Advances II and all other Obligations.

 

“Cash-Secured Advance II” means an advance made by Lender to Borrowers under Section 1.1(c) of this Agreement.

 

 

3

 

  

“Cash-Secured Advances II Maturity Date” means February 3, 2017.

 

“Cash-Secured Credit Limit II” means $3,000,000, which is intended to be the maximum amount of Cash-Secured Advances II at any time outstanding.

 

7.              Amendment to Section 15. Section 15 of the Agreement is hereby amended in its entirety as follows:

 

	 	
15.
	
EXECUTION, EFFECTIVENESS, SURVIVAL. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Agreement and the other documents executed in connection herewith constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. Delivery of an executed counterpart of a signature page of this Agreement by telecopy shall be effective as delivery of a manually executed counterpart of this Agreement. This Agreement shall become effective upon the execution and delivery hereof by Borrowers and Lender, and shall continue in full force and effect until all Obligations have been paid in full and all of Lender’s obligations hereunder have been terminated. Lender reserves the right to issue press releases, advertisements, and other promotional materials describing any successful outcome of services provided on Borrowers’ behalf. Each Borrower agrees that Lender shall have the right to identify such Borrower by name in those materials.

 

8.             Conditions Precedent to Effectiveness of Amendment. The effectiveness of this Amendment is subject to and contingent upon the fulfillment of each and every one of the following conditions to the satisfaction of Lender:

 

(a)            Lender shall have received this Amendment, duly executed by Borrowers;

 

(b)            Lender shall have received a limited continuing guaranty of the Cash-Secured Advances II, duly executed by Alliance and otherwise in form and substance satisfactory to Lender;

 

(c)            Lender shall have received a collateral pledge agreement of the Cash Collateral II, duly executed by Alliance and otherwise in form and substance satisfactory to Lender;

 

(d)            Lender shall have received the Cash Collateral II in accordance with the collateral pledge agreement described above; 

 

(e)            Lender shall have received the Facility Fee with respect to the Cash-Secured Credit Limit II in the amount of $22,500, which Facility Fee shall be fully earned and non-refundable.

 

(f)            No Event of Default or Default shall have occurred and be continuing; and

 

(g)           All of the representations and warranties set forth herein and in the Agreement shall be true, complete and accurate in all respects as of the date hereof (except for representations and warranties which are expressly stated to be true and correct as of the date of the Agreement).

 

9.            Representations and Warranties. In order to induce Lender to enter into this Amendment, each Borrower hereby represents and warrants to Lender that:

 

(a)           No Event of Default or Default is continuing;

 

 

4

 

  

(b)          All of the representations and warranties set forth herein and in the Agreement are true, complete and accurate in all respects (except for representations and warranties which are expressly stated to be true and correct as of the date of the Agreement); and

 

(c)          This Amendment has been duly executed and delivered by Borrowers, and the Agreement continues to constitute the legal, valid and binding agreements and obligations of Borrowers, enforceable in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency, and similar laws and equitable principles affecting the enforcement of creditors’ rights generally.

 

10.          Counterparts; Telefacsimile Execution. This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Amendment. Delivery of an executed counterpart of this Amendment by telefacsimile shall be equally as effective as delivery of a manually executed counterpart of this Amendment. Any party delivering an executed counterpart of this Amendment by telefacsimile also shall deliver a manually executed counterpart of this Amendment but the failure to deliver a manually executed counterpart shall not affect the validity, enforceability, and binding effect of this Amendment.

 

11.          Integration. The Agreement as amended by this Amendment constitutes the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and thereof, and supersedes any and all prior agreements and understandings, oral or written, relating to the subject matter hereof and thereof.

 

12.          No Waiver. The execution of this Amendment and the acceptance of all other agreements and instruments related hereto shall not be deemed to be a waiver of any Default or Event of Default, whether or not known to Lender and whether or not existing on the date of this Amendment.

 

13.          Release.

 

(a)     Each Borrower hereby absolutely and unconditionally releases and forever discharges Lender, and any and all participants, parent corporations, subsidiary corporations, affiliated corporations, insurers, indemnitors, successors and assigns thereof, together with all of the present and former directors, officers, agents and employees of any of the foregoing, from any and all claims, demands or causes of action of any kind, nature or description, whether arising in law or equity or upon contract or tort or under any state or federal law or otherwise, which such Borrower has had, now has or has made claim to have against any such person for or by reason of any act, omission, matter, cause or thing whatsoever arising from the beginning of time to and including the date of this Amendment, whether such claims, demands and causes of action are matured or unmatured or known or unknown. Each Borrower certifies that it has read the following provisions of California Civil Code Section 1542:

 

A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.

 

(b)     Each Borrower understands and acknowledges that the significance and consequence of this waiver of California Civil Code Section 1542 is that even if it should eventually suffer additional damages arising out of the facts referred to above, it will not be able to make any claim for those damages. Furthermore, each Borrower acknowledges that it intends these consequences even as to claims for damages that may exist as of the date of this release but which it does not know exist, and which, if known, would materially affect its decision to execute this Agreement, regardless of whether its lack of knowledge is the result of ignorance, oversight, error, negligence, or any other cause.

 

 

5

 

  

14.          Reaffirmation of the Agreement. The Agreement as amended hereby remains in full force and effect.

 

[remainder of page intentionally left blank]

 

 

6

 

 

IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Amendment as of the date first hereinabove written.

 

	
 
	
DETERMINE INC.,
	
 

	 	a Delaware corporation	 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
By: 
	
 
	
 

	
 
	
Name: 
	
 
	
 

	
 
	
Title: 
	
 
	
 

	 	 	 	 
	 	 	 	 
	 	DETERMINE SOURCING, INC.,	 
	 	a Delaware corporation	 
	 	 	 	 
	 	 	 	 
	 	By:	 	 
	 	Name:	 	 
	 	Title:	 	 

 

 

 

Amendment Number Five to Amended and Restated Business Financing Agreement

 

 

 

 

 

 

	
 
	
WESTERN ALLIANCE BANK,
	
 

	 	an Arizona corporation 	 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
By: 
	
 
	
 

	
 
	
Name:
	
 
	
 

	
 
	
Title:
	
 
	
 

 

 

 

Amendment Number Five to Amended and Restated Business Financing Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]